Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

2018 Annual Meeting | C224 - Neuromyelitis Optica Spectrum Disorders

Friday 04/27/18
01:00 PM - 03:00 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Seminar
Dean M. Wingerchuk, MD, FÂ鶹´«Ã½Ó³»­
Participants should be able to understand the clinical, neuroimaging, laboratory, and pathologic characteristics of NMOSD; compare the utility of AQP4-IgG assay methods; recognize clinical characteristics associated with MOG-IgG; be able to discuss elements of the newly revised NMOSD diagnostic criteria; and describe approaches to prevention and treatment of acute NMOSD attacks.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge
Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider
Case-based, Didactic, Interactive, Audience Participation
Event Timeline
01:00 PM - 01:45 PM Speaker NMOSD: Pathogenesis and Clinical Diagnosis
Brian G. Weinshenker, MD, FÂ鶹´«Ã½Ó³»­
01:45 PM - 02:30 PM Speaker NMOSD: Current and Emerging Therapies and Strategies
Dean M. Wingerchuk, MD, FÂ鶹´«Ã½Ó³»­
02:30 PM - 03:00 PM Speaker Case-based Discussion
Brian G. Weinshenker, MD, FÂ鶹´«Ã½Ó³»­, Dean M. Wingerchuk, MD, FÂ鶹´«Ã½Ó³»­
Faculty Disclosures
Dean M. Wingerchuk, MD, FÂ鶹´«Ã½Ó³»­ Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyer Squibb. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwers.
Brian G. Weinshenker, MD, FÂ鶹´«Ã½Ó³»­ Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zenas Pharma. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.